$PBLA
Panbela Therapeutics, Inc.

2019 Q1 Form 10-K Financial Statement

#000143774919005461 Filed on March 22, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q4 2017 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $300.0K $330.0K $1.170M
YoY Change -54.55% -71.79% -7.87%
% of Gross Profit
Research & Development $350.0K $310.0K $640.0K
YoY Change -39.66% -51.56% -24.71%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $350.0K $640.0K $1.810M
YoY Change -39.66% -64.64% -14.22%
Operating Profit -$653.0K
YoY Change -47.25%
Interest Expense $1.033M -$50.00K -$470.0K
YoY Change 118.39% -89.36% 840.0%
% of Operating Profit
Other Income/Expense, Net -$999.0K -$140.0K $40.00K
YoY Change 83.98% -450.0% -123.53%
Pretax Income -$1.652M -$830.0K -$2.240M
YoY Change -7.24% -62.95% -3.86%
Income Tax -$71.00K -$90.00K -$80.00K
% Of Pretax Income
Net Earnings -$1.581M -$740.0K -$2.160M
YoY Change -9.81% -65.74% -3.57%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$311.6K -$145.7K -$582.2K
COMMON SHARES
Basic Shares Outstanding 5.070M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q4 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.380M $1.410M $150.0K
YoY Change 17.95% 840.0% -65.91%
Cash & Equivalents $1.379M $1.405M $152.0K
Short-Term Investments
Other Short-Term Assets $70.00K $110.0K $200.0K
YoY Change -53.33% -45.0% 66.67%
Inventory
Prepaid Expenses $73.00K $110.0K $195.0K
Receivables
Other Receivables
Total Short-Term Assets $1.860M $1.847M $767.0K
YoY Change 5.14% 140.81% -12.54%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $51.00K $51.00K
YoY Change -8.93%
Total Long-Term Assets $51.00K $51.00K $0.00
YoY Change -8.93%
TOTAL ASSETS
Total Short-Term Assets $1.860M $1.847M $767.0K
Total Long-Term Assets $51.00K $51.00K $0.00
Total Assets $1.911M $1.898M $767.0K
YoY Change 4.71% 147.46% -12.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $905.0K $1.064M $1.196M
YoY Change -25.94% -11.04% -3.94%
Accrued Expenses $200.0K $216.0K $1.254M
YoY Change 112.77% -82.78% 48.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $259.0K $286.0K $14.00K
YoY Change 418.0% 1942.86% -95.24%
Total Short-Term Liabilities $2.499M $1.630M $4.170M
YoY Change -35.84% -60.91% -24.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $286.0K
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $286.0K
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.499M $1.630M $4.170M
Total Long-Term Liabilities $0.00 $286.0K
Total Liabilities $2.500M $1.630M $4.456M
YoY Change -39.69% -63.42% -19.26%
SHAREHOLDERS EQUITY
Retained Earnings -$36.64M -$35.06M -$29.15M
YoY Change 18.55% 20.26% 55.24%
Common Stock $5.000K $5.000K $4.000K
YoY Change 25.0% 25.0% 33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$588.0K $268.0K -$3.689M
YoY Change
Total Liabilities & Shareholders Equity $1.911M $1.898M $767.0K
YoY Change 4.71% 147.46% -12.54%

Cashflow Statement

Concept 2019 Q1 2018 Q4 2017 Q4
OPERATING ACTIVITIES
Net Income -$1.581M -$740.0K -$2.160M
YoY Change -9.81% -65.74% -3.57%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$783.0K -$160.0K -$790.0K
YoY Change 33.16% -79.75% -4.82%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $27.00K
YoY Change
Cash From Financing Activities 758.0K 1.330M 0.000
YoY Change -52.95% -100.0%
NET CHANGE
Cash From Operating Activities -783.0K -160.0K -790.0K
Cash From Investing Activities
Cash From Financing Activities 758.0K 1.330M 0.000
Net Change In Cash -25.00K 1.170M -790.0K
YoY Change -102.44% -248.1% 1.28%
FREE CASH FLOW
Cash From Operating Activities -$783.0K -$160.0K -$790.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Type
DocumentType
10-K
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5070341
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018Q2 dei Entity Public Float
EntityPublicFloat
23751819
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2017 snbp Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
19000
CY2017Q4 snbp Changes In Gross Deferred Tax Assets Due To Changes In Enacted Tax Rate
ChangesInGrossDeferredTaxAssetsDueToChangesInEnactedTaxRate
-1800000
CY2018Q4 snbp Clinical Trial Related Liabilities Current
ClinicalTrialRelatedLiabilitiesCurrent
42000
CY2017Q4 snbp Clinical Trial Related Liabilities Current
ClinicalTrialRelatedLiabilitiesCurrent
95000
CY2018Q4 snbp Common Shares Issued Upon Conversion Of Notes Payable
CommonSharesIssuedUponConversionOfNotesPayable
383947
CY2018 snbp Debt Conversion Conversion Of Demand Notes Into Common Stock
DebtConversionConversionOfDemandNotesIntoCommonStock
CY2017 snbp Debt Conversion Conversion Of Demand Notes Into Common Stock
DebtConversionConversionOfDemandNotesIntoCommonStock
250000
CY2018 snbp Debt Conversion Conversion Of Promissory Notes And Accrued Interest Into Common Stock
DebtConversionConversionOfPromissoryNotesAndAccruedInterestIntoCommonStock
CY2017 snbp Debt Conversion Conversion Of Promissory Notes And Accrued Interest Into Common Stock
DebtConversionConversionOfPromissoryNotesAndAccruedInterestIntoCommonStock
2888000
CY2018 snbp Debt Conversion Conversion Of Promissory Notes And Accrued Interest Into Common Stock And Warrants
DebtConversionConversionOfPromissoryNotesAndAccruedInterestIntoCommonStockAndWarrants
3258000
CY2017 snbp Debt Conversion Conversion Of Promissory Notes And Accrued Interest Into Common Stock And Warrants
DebtConversionConversionOfPromissoryNotesAndAccruedInterestIntoCommonStockAndWarrants
CY2018Q2 snbp Debt Instrument Convertible Gross Proceeds From Sale Of Equity Trigger
DebtInstrumentConvertibleGrossProceedsFromSaleOfEquityTrigger
2000000
CY2018Q4 snbp Deferred Tax Liabilities Beneficial Conversion Feature Net
DeferredTaxLiabilitiesBeneficialConversionFeatureNet
283000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5077483
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3841652
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2017Q4 snbp Deferred Tax Liabilities Beneficial Conversion Feature Net
DeferredTaxLiabilitiesBeneficialConversionFeatureNet
338000
CY2018 snbp Effective Income Tax Rate Reconciliation Deferred True Up Percent
EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent
CY2017 snbp Effective Income Tax Rate Reconciliation Deferred True Up Percent
EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent
0.03
CY2018 snbp Effective Income Tax Rate Reconciliation Foreign Research Incentives Percent
EffectiveIncomeTaxRateReconciliationForeignResearchIncentivesPercent
0.057
CY2017 snbp Effective Income Tax Rate Reconciliation Foreign Research Incentives Percent
EffectiveIncomeTaxRateReconciliationForeignResearchIncentivesPercent
0.038
CY2018 snbp Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.001
CY2017 snbp Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.135
CY2018Q4 snbp Grant Agreement Total Grants
GrantAgreementTotalGrants
225000
CY2018 snbp Grant Income Nonoperating
GrantIncomeNonoperating
54000
CY2017 snbp Grant Income Nonoperating
GrantIncomeNonoperating
163000
CY2018 snbp Increase Decrease In Operating Expense
IncreaseDecreaseInOperatingExpense
-179000
CY2018 snbp Intrinsic Value Of Convertible Debt With Conversion Feature
IntrinsicValueOfConvertibleDebtWithConversionFeature
716000
CY2017 snbp Intrinsic Value Of Convertible Debt With Conversion Feature
IntrinsicValueOfConvertibleDebtWithConversionFeature
2954000
CY2018 snbp Noncash Interest Expense
NoncashInterestExpense
4000
CY2017 snbp Noncash Interest Expense
NoncashInterestExpense
162000
CY2017 snbp Sharebased Compensation Arrangement By Sharebased Payment Award Number Of Shares Available For Grant Grants In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod
54000
CY2018 snbp Sharebased Compensation Arrangement By Sharebased Payment Award Number Of Shares Available For Grant Grants In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod
404000
CY2018 snbp Stock Issued During Period Value Conversion Of Convertible Securities Into Common Stock And Warrants
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesIntoCommonStockAndWarrants
3258000
CY2017 snbp Stock Issued During Period Value Conversion Of Demand Notes Payable
StockIssuedDuringPeriodValueConversionOfDemandNotesPayable
-993000
CY2018 snbp Stock Options Granted In Exchange For Release From Contingent Payment Obligations
StockOptionsGrantedInExchangeForReleaseFromContingentPaymentObligations
1094000
CY2017 snbp Stock Options Granted In Exchange For Release From Contingent Payment Obligations
StockOptionsGrantedInExchangeForReleaseFromContingentPaymentObligations
CY2018Q4 snbp Working Capital
WorkingCapital
-1100000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1064000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1196000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
212000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1254000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
157000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
61000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
283000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-165000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
35038000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
25625000
CY2017 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
2954000
CY2018 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
716000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1733000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2373000
CY2018 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
739000
CY2017 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
263000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
495000
CY2018 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1732000
CY2017 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1387000
CY2018 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
9000
CY2017 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
56000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3451355
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1204653
CY2018Q4 us-gaap Assets
Assets
1898000
CY2017Q4 us-gaap Assets
Assets
767000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
1847000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
767000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1405000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
152000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
438000
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1253000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-286000
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2035197
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4183504
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5077483
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3841652
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5457000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10615000
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentration of </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">c</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">redit </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">r</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">isk</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Financial instruments that potentially subject the company to significant concentrations of credit risk consist primarily of cash. Cash is deposited in demand accounts at commercial banks. At times, such deposits <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be in excess of insured limits. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> experienced any losses on its deposits of cash.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div>
CY2018Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
64000
CY2017Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1525000
CY2018Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1300000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
6084000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
4417000
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
283000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
338000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4807000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3440000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
71000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
212000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
235000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
235000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
971000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
530000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5801000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4079000
CY2018Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
283000
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
338000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.27
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.91
CY2018 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-3000
CY2017 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
10000
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.057
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.038
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1630000
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.226
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.066
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.006
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.172
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.009
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.003
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1094000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2108000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3423000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-6159000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-10910000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-254000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-536000
CY2018Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
332000
CY2017Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
420000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
360000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-319000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
59000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
402000
CY2018 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-50000
CY2017 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
70000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-25000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
75000
CY2018 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
CY2017 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
3696000
CY2018 us-gaap Interest Expense
InterestExpense
1814000
CY2017 us-gaap Interest Expense
InterestExpense
1617000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
67000
CY2017 us-gaap Interest Paid Net
InterestPaidNet
11000
CY2018Q4 us-gaap Interest Payable Current
InterestPayableCurrent
4000
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
181000
CY2018 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
CY2017 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1898000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
767000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4170000
CY2018Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
CY2017Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
286000
CY2018Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
286000
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
14000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
286000
CY2018 us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div> </div></div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Risks and Uncertainties</div></div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (&#x201c;FDA&#x201d;) in the United States, the Therapeutic Goods Administration (&#x201c;TGA&#x201d;) in Australia, the European Medicines Agency (&#x201c;EMA&#x201d;) in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>take many years, and is normally expected to involve substantial expenditures.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have incurred losses of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$35.1</div> million since our inception in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011.</div> For the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>we incurred a net loss and negative cash flows from operating activities of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.9</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.4</div> million, respectively. We expect to incur substantial losses for the foreseeable future, which will continue to generate negative net cash flows from operating activities, as we continue to pursue research and development activities and the clinical development of our primary product candidate, SBP-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">101.</div> As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>we had cash of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.4</div> million, negative working capital of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.1</div> million (excluding a debt discount of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.3</div> million) and stockholders&#x2019; equity of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.3</div> million. The Company&#x2019;s principal sources of cash have included the issuance of convertible debt and equity securities.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The accompanying Consolidated Financial Statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business and do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties. Our ability to continue as a going concern, realize the carrying value of our assets and discharge our liabilities in the ordinary course of business is dependent upon a number of factors, including our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our initial product candidate, SBP-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">101,</div> in the United States, Australia, the European Union or other markets and ultimately our ability to market and sell our initial product candidate. These factors, among others, raise substantial doubt about our ability to continue operations as a going concern.</div></div>
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3643000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3106000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2387000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3402000
us-gaap Net Income Loss
NetIncomeLoss
35100000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-5905000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-10374000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2268000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4894000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-3891000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-6016000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
51000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
CY2018 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
448000
CY2017 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-241000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-508000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
255000
CY2018 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
5000
CY2017 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
16000
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
27000
CY2017 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
110000
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
195000
CY2018 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1329000
CY2017 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3059000
CY2018 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
2328000
CY2017 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
28000
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1114400
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.72
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
732149
CY2017 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
19000
CY2018 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
14000
CY2017 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1783000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2593000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-35058000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-29153000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1060400
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
1279000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
1733000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
75749
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
54000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
404000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.69
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3896235
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2121985
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
169495
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
701960
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
733960
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1032211
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.50
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.79
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.90
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.25
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.20
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.34
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.49
CY2018Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
989711
CY2018Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1032211
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
135200
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
42500
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
27949
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
9.68
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
9.31
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.83
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
468751
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
9.43
CY2018 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P7Y135D
CY2018Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
8.904
CY2018 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y135D
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
22000
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
30000
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
5841000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2328000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
268000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-3689000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-4642000
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of estimates</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The preparation of Consolidated Financial Statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div>
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4662080
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3566098

Files In Submission

Name View Source Status
0001437749-19-005461-index-headers.html Edgar Link pending
0001437749-19-005461-index.html Edgar Link pending
0001437749-19-005461.txt Edgar Link pending
0001437749-19-005461-xbrl.zip Edgar Link pending
ex_137872.htm Edgar Link pending
ex_137873.htm Edgar Link pending
ex_137874.htm Edgar Link pending
ex_137875.htm Edgar Link pending
ex_137876.htm Edgar Link pending
ex_138423.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sbpgraph1.jpg Edgar Link pending
Show.js Edgar Link pending
snbp-20181231.xml Edgar Link completed
snbp-20181231.xsd Edgar Link pending
snbp-20181231_cal.xml Edgar Link unprocessable
snbp-20181231_def.xml Edgar Link unprocessable
snbp-20181231_lab.xml Edgar Link unprocessable
snbp-20181231_pre.xml Edgar Link unprocessable
snbp20181231_10k.htm Edgar Link pending
snbp20181231_10kimg002.gif Edgar Link pending
snbp20181231_10kimg003.gif Edgar Link pending
snbp20181231_10kimg004.gif Edgar Link pending